ArticleActa neurochirurgica2026
Surpass evolve flow diverter in intracranial aneurysms: results from a single-center cohort with extended follow-up.
Article in Acta neurochirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Surpass Evolve (SE) is a second-generation flow diverter (FD) designed to improve procedural performance compared with earlier devices. This study aimed to evaluate the angiographic efficacy, safety, and clinical outcomes of SE in a single-center cohort with extended follow-up, comparing it to earlier-generation FDs.
methodsWe conducted a single-center comparative cohort study including 120 patients with unruptured intracranial aneurysms treated between 2014 and 2023. The prospective SE cohort (n = 67) was compared to a retrospective control cohort (n = 53; Surpass Streamline [SS] and Pipeline Embolization Device [PED]). Primary outcomes were complete aneurysm occlusion, major stroke, in-stent thrombosis, aneurysm enlargement, and unfavorable functional outcome. Secondary analyses included a composite safety endpoint and procedural parameters. Propensity score matching (PSM) was additionally performed to adjust for baseline imbalances, while multivariate Cox regression was used in the entire cohort to maximize statistical power.
resultsComplete occlusion was achieved in 79.1% of the SE cohort, with major stroke and in-stent thrombosis occurring in 1.5% each, and aneurysm enlargement in 3.0%. At last follow-up, 98.5% of SE patients had favorable functional outcomes (mRS 0-2). Compared with controls, the SE cohort had significantly fewer major strokes (1.5% vs. 13.2%, p = 0.029) and lower aneurysm enlargement (3.0% vs. 22.6%, p = 0.002). These findings remained consistent in the PSM-matched cohort, particularly regarding the prevention of aneurysm enlargement (p = 0.012). Procedural time was shorter (p = 0.001), and balloon angioplasty was less frequent (p = 0.023). SE use was independently associated with reduced aneurysm enlargement (adjusted OR, 0.14; p = 0.019). Cox analysis showed SS had lower occlusion probability (HR, 0.58; p = 0.047) than SE, while PED was similar.
conclusionsIn this single-center comparative cohort, SE demonstrated a favorable safety and efficacy profile, with lower rates of major stroke and aneurysm enlargement and improved procedural efficiency compared with earlier-generation devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.